Clinical Scorecard: PRP Treatment in the Clinic

At a Glance

Key Highlights

• PRP is richer in anti-inflammatory mediators and growth factors than autologous serum (AS).
• Significant improvements in DED symptoms observed with PRP compared to AS.
• PRP can be microneedled into skin around meibomian and lacrimal glands to enhance function.
• NGF delivered via PRP shows potential for corneal nerve regeneration.
• PRP technology advancements improve yield and patient outcomes.

Guideline-Based Recommendations

Diagnosis

• Evaluate superficial corneal staining and Ocular Surface Disease Index (OSDI) scores.

Management

• Use PRP as therapeutic drops for DED and neuropathic pain.

Monitoring & Follow-up

• Monitor corneal nerve health using corneal confocal microscopy (CCM).

Risks

• Potential for clotting and bacterial growth if PRP is not properly stored.

Patient & Prescribing Data

Patients with severe dry eye disease and associated neuropathic pain.

PRP shows superior efficacy in improving symptoms and nerve growth compared to traditional treatments.

Clinical Best Practices

• Utilize PRP for both drops and injections to enhance ocular surface health.
• Implement microneedling techniques for safer gland function enhancement.
• Stay updated with advancements in PRP extraction technologies.

References

• International Society of Ophthalmological and Therapeutics (ISOPT) Meeting 2018
• Fox et al. on autologous serum for keratoconjunctivitis sicca
• Tsubota et al. on AS for Sjögren’s syndrome